IMTX:NASDAQImmatics N.V. Analysis

Immatics is trading below its short‑term moving averages, with the price under the 20‑day and 50‑day SMAs and a sub‑50 RSI indicating near‑oversold conditions. The MACD remains in a bearish configuration and the chart shows a clear downward bias, while volume has been picking up, suggesting that sellers are still in control but market participation is rising.
Fundamentally the company reports steep revenue decline, negative margins and no earnings, yet it holds a sizable cash buffer relative to modest debt. The price‑to‑sales multiple is extremely elevated and the PE is negative, but analysts have issued a strong‑buy consensus, largely driven by an upcoming Phase 1b data read‑out at the ESMO Congress and a pipeline focused on PRAME‑targeted T‑cell therapies.